COMP <GO>
CRMD vs MRK // EV/EBITDA & P/E VALUATION
CorMedix Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: CRMD 8
— MRK 4
▲ EV/EBITDA & P/E VALUATION LEADER: CRMD
LAST: $5.70 (-25.46%) • MKT CAP: $595.5M
valuation
3.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRMD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRMD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 74.80% | +13.70 | CRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 45.50% | 20.70% | +24.80 | CRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 3.0x | 15.3x | -12.30 | CRMD | /valuation <GO> |
| Free Cash Flow Yield | — | 3.42% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 48.20% | 34.30% | +13.90 | CRMD | /operating-margins <GO> |
| Net Profit Margin | 52.30% | 28.10% | +24.20 | CRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | CRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.81 | 5.19 | -3.38 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | CRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.6 | 51.7 | -1.10 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | 18.4x | -14.90 | CRMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $595.5M | $361.02B | -$360.43B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRMD REV | MRK REV | CRMD GROSS % | MRK GROSS % | CRMD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $311.7M | $65.01B | 88.5% | 74.8% | $172.8M | $12.36B |
| FY 2024 | $43.5M | $64.17B | 92.7% | 76.3% | -$50.7M | $18.10B |
| FY 2023 | $0 | $60.12B | — | — | -$38.4M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRMD // BETA —
MRK // BETA 0.92